(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 34.43% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.98%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Aquestive Therapeutics's revenue in 2026 is $44,545,000.On average, 11 Wall Street analysts forecast AQST's revenue for 2026 to be $5,984,234,888, with the lowest AQST revenue forecast at $5,465,909,565, and the highest AQST revenue forecast at $6,471,438,723. On average, 10 Wall Street analysts forecast AQST's revenue for 2027 to be $8,952,370,479, with the lowest AQST revenue forecast at $6,243,336,527, and the highest AQST revenue forecast at $14,352,497,762.
In 2028, AQST is forecast to generate $13,643,416,028 in revenue, with the lowest revenue forecast at $11,194,948,255 and the highest revenue forecast at $18,464,195,463.